Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntraDose (Cisplatin/Epinephrine) in Recurrent/Refractory Head and Neck Cancer
NCT00002659Phase 3Unknown
- Sponsor
- Matrix Pharmaceutical
- Start
- May 1995
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Cisplatin/Epinephrine Gel with Placebo Gel (2 arms). Primary endpoints: Objective Response Rate of Target Tumor at 8 weeks and Achievement of Treatment Goal (Patient Benefit) at 8 weeks. Status: unknown.
02
Drugs
cisplatinepinephrine
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00002659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002659.